← Back to all trials
Active Not Recruiting
NCT06577194
Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01)
Conditions: Rectal Cancer, Advanced Solid Tumor
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 35
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Location: Jiangsu Province Hospital Nanjing Jiangsu
Summary
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer
Eligibility Criteria
Inclusion Criteria:
* Age 18 to 70 years at enrollment.
* Histologically confirmed rectal adenocarcinoma with the inferior tumor border within 12 cm of the anal verge.
* Pelvic MRI stage T3-T4, or any T stage with regional lymph-node involvement.
* Absolute neutrophil count \>=1.5 x 10\^9/L and platelet count \>=75 x 10\^9/L.
* Total bilirubin \
Source: ClinicalTrials.gov (NCT06577194). StuddyBuddy aggregates publicly available trial information.
